Recursion Pharmaceuticals (NASDAQ:RXRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Recursion Pharmaceuticals (NASDAQ:RXRX) from a strong sell rating to a sell rating in a report published on Saturday,Wall Street Zen reports.

Other equities analysts have also recently issued research reports about the company. Morgan Stanley set a $5.90 target price on Recursion Pharmaceuticals in a report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $8.18.

Recursion Pharmaceuticals Stock Up 4.3%

NASDAQ:RXRX opened at $3.61 on Friday. Recursion Pharmaceuticals has a 12-month low of $2.77 and a 12-month high of $7.18. The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $1.93 billion, a P/E ratio of -3.47 and a beta of 1.04. The stock’s fifty day simple moving average is $3.64 and its 200-day simple moving average is $3.42.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). The company had revenue of $7.67 million for the quarter, compared to analyst estimates of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%. During the same period last year, the firm earned ($0.41) earnings per share. Equities research analysts expect that Recursion Pharmaceuticals will post -0.94 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Najat Khan sold 22,408 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $3.52, for a total value of $78,876.16. Following the completion of the transaction, the chief executive officer owned 2,072,890 shares in the company, valued at $7,296,572.80. This represents a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $4.84, for a total transaction of $242,000.00. Following the completion of the transaction, the director owned 6,108,287 shares of the company’s stock, valued at $29,564,109.08. This trade represents a 0.81% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 157,408 shares of company stock worth $643,576. Company insiders own 6.65% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in RXRX. MCF Advisors LLC bought a new stake in Recursion Pharmaceuticals in the 2nd quarter valued at $27,000. Fund Advisors of America Inc FL bought a new position in Recursion Pharmaceuticals during the 2nd quarter worth about $45,000. Integral Investment Advisors Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at about $39,000. MQS Management LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at about $41,000. Finally, Sequoia Financial Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 51.5% in the first quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company’s stock valued at $47,000 after purchasing an additional 5,156 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.